Literature DB >> 34102641

Adult Pulmonary Intensive and Intermediate Care Units: The Italian Thoracic Society (ITS-AIPO) Position Paper.

Teresa Renda1, Raffaele Scala2, Antonio Corrado3, Nicolino Ambrosino4, Adriano Vaghi5.   

Abstract

The imbalance between the prevalence of patients with acute respiratory failure (ARF) and acute-on-chronic respiratory failure and the number of intensive care unit (ICU) beds requires new solutions. The increasing use of non-invasive respiratory tools to support patients at earlier stages of ARF and the increased expertise of non-ICU clinicians in other types of supportive care have led to the development of adult pulmonary intensive care units (PICUs) and pulmonary intermediate care units (PIMCUs). As in other European countries, Italian PICUs and PIMCUs provide an intermediate level of care as the setting designed for managing ARF patients without severe non-pulmonary dysfunction. The PICUs and PIMCUs may also act as step-down units for weaning patients from prolonged mechanical ventilation and for discharging patients still requiring ventilatory support at home. These units may play an important role in the on-going coronavirus disease 2019 pandemic. This position paper promoted by the Italian Thoracic Society (ITS-AIPO) describes the models, facilities, staff, equipment, and operating methods of PICUs and PIMCUs.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Acute respiratory failure; Cost-effectiveness; Intensive care units; Pulmonologist; Respiratory care units

Year:  2021        PMID: 34102641     DOI: 10.1159/000516332

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  1 in total

1.  Pulmonologist-Administered Balanced Propofol Analgosedation during Interventional Procedures: An Italian Real-Life Study on Comfort and Safety.

Authors:  Rosalba Maffucci; Uberto Maccari; Luca Guidelli; Lucia Benedetti; Roberto Fabbroni; Bruno Piccoli; Andrea Bianco; Raffaele Scala
Journal:  Int J Clin Pract       Date:  2022-06-13       Impact factor: 3.149

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.